Abu Dhabi has received the first global shipment of AstraZeneca’s new COVID-19 medication, after gaining emergency use authorisation from the UAE’s Ministry of Health and Prevention.
The long-acting antibody medication, Evusheld, is designed to prevent severe infection and death amongst immunocompromised patients.
It will be added to the existing COVID-19 drugs that are already available within Abu Dhabi and the UAE to ensure the continuity of world-class care.
The first doses of Evusheld arrived in Abu Dhabi on Monday following a collaboration of key partners including Rafed, the UAE’s Primary Group Purchasing Organisation, along with Etihad Cargo, AstraZeneca and Abu Dhabi Airports Company.
The breakthrough medication will be stored at Rafed’s distribution centre to be transported to various destinations.
The collaboration is another key milestone for healthcare, logistics and supply chain entities that continue to contribute to the evolution of Abu Dhabi’s medical sector.
.@DoHSocial has received the first global shipment of AstraZeneca’s Evusheild (formerly AZD7442), a medication to protect immunocompromised patients against Covid-19. pic.twitter.com/RHf61XcmMU
— مكتب أبوظبي الإعلامي (@ADMediaOffice) December 20, 2021
UAE condemns terrorist plots in Morocco, supports safety measures
Mohamed bin Zayed University for Humanities receives International Quality Accreditation
UAE ministry revokes licence of private university over 'severe violations'
UAE expresses solidarity with Ghana and Ivory Coast following floods
DEWA deploys agentic AI across its digital platforms
